Cytochalasin BCAS# 14930-96-2 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 14930-96-2 | SDF | Download SDF |
| PubChem ID | 5311281 | Appearance | Powder |
| Formula | C29H37NO5 | M.Wt | 479.61 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (208.50 mM) Ethanol : 25 mg/mL (52.13 mM; Need ultrasonic) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (1S,4E,6R,10R,12E,14S,15S,17S,18S,19S)-19-benzyl-6,15-dihydroxy-10,17-dimethyl-16-methylidene-2-oxa-20-azatricyclo[12.7.0.01,18]henicosa-4,12-diene-3,21-dione | ||
| SMILES | CC1CCCC(C=CC(=O)OC23C(C=CC1)C(C(=C)C(C2C(NC3=O)CC4=CC=CC=C4)C)O)O | ||
| Standard InChIKey | GBOGMAARMMDZGR-TYHYBEHESA-N | ||
| Standard InChI | InChI=1S/C29H37NO5/c1-18-9-7-13-22(31)15-16-25(32)35-29-23(14-8-10-18)27(33)20(3)19(2)26(29)24(30-28(29)34)17-21-11-5-4-6-12-21/h4-6,8,11-12,14-16,18-19,22-24,26-27,31,33H,3,7,9-10,13,17H2,1-2H3,(H,30,34)/b14-8+,16-15+/t18-,19-,22-,23+,24+,26+,27-,29-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Cytochalasin B induces membrane vesicles convey angiogenic activity of parental cells. 2. Cytochalasin B can exert its inhibitory effect on DNA synthesis by inhibiting glucose transport. 3. Cytochalasin B triggers a novel pertussis toxin sensitive pathway in TNF-alpha primed neutrophils. 4. Cytochalasin B is a phytotoxin. |
| Targets | VEGFR | DNA/RNA Synthesis | TNF-α |
Cytochalasin B Dilution Calculator
Cytochalasin B Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.085 mL | 10.4251 mL | 20.8503 mL | 41.7005 mL | 52.1257 mL |
| 5 mM | 0.417 mL | 2.085 mL | 4.1701 mL | 8.3401 mL | 10.4251 mL |
| 10 mM | 0.2085 mL | 1.0425 mL | 2.085 mL | 4.1701 mL | 5.2126 mL |
| 50 mM | 0.0417 mL | 0.2085 mL | 0.417 mL | 0.834 mL | 1.0425 mL |
| 100 mM | 0.0209 mL | 0.1043 mL | 0.2085 mL | 0.417 mL | 0.5213 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- pp60 c-src (521-533) (phosphorylated)
Catalog No.:BCC5851
CAS No.:149299-77-4
- 1-Dehydroxy-23-deoxojessic acid
Catalog No.:BCN1663
CAS No.:149252-87-9
- De-4'-O-methylyangambin
Catalog No.:BCN1662
CAS No.:149250-48-6
- Neotripterifordin
Catalog No.:BCN7477
CAS No.:149249-32-1
- Arcaine sulfate
Catalog No.:BCC6631
CAS No.:14923-17-2
- Z-Ser(Tos)-OMe
Catalog No.:BCC2741
CAS No.:1492-52-0
- H-Abu-OH
Catalog No.:BCC3198
CAS No.:1492-24-6
- Benserazide HCl
Catalog No.:BCC4468
CAS No.:14919-77-8
- (±)-Myristoylcarnitine chloride
Catalog No.:BCC6698
CAS No.:14919-38-1
- (±)-Decanoylcarnitine chloride
Catalog No.:BCC6659
CAS No.:14919-36-9
- CGP 55845 hydrochloride
Catalog No.:BCC5737
CAS No.:149184-22-5
- CGP 54626 hydrochloride
Catalog No.:BCC6934
CAS No.:149184-21-4
- AACOCF3
Catalog No.:BCC7075
CAS No.:149301-79-1
- UNC2250
Catalog No.:BCC4876
CAS No.:1493694-70-4
- 1,2,3,4,6-O-Pentagalloylglucose
Catalog No.:BCN2338
CAS No.:14937-32-7
- UNC2881
Catalog No.:BCC5362
CAS No.:1493764-08-1
- Cidofovir dihydrate
Catalog No.:BCC4247
CAS No.:149394-66-1
- NE 100 hydrochloride
Catalog No.:BCC7573
CAS No.:149409-57-4
- Poncirin
Catalog No.:BCN2590
CAS No.:14941-08-3
- Traxillaside
Catalog No.:BCN6917
CAS No.:149415-62-3
- Hypocrellin C
Catalog No.:BCN3398
CAS No.:149457-83-0
- Ganoderic acid AM1
Catalog No.:BCN2441
CAS No.:149507-55-1
- Marmin
Catalog No.:BCN1665
CAS No.:14957-38-1
- Stachybotramide
Catalog No.:BCN6969
CAS No.:149598-71-0
Cytochalasin B triggers a novel pertussis toxin sensitive pathway in TNF-alpha primed neutrophils.[Pubmed:15157285]
BMC Cell Biol. 2004 May 24;5:21.
BACKGROUND: Cytochalasin B does not directly activate the oxygen-radical-producing NADPH oxidase activity of neutrophils but transfers desensitized G-protein coupled receptors (GPCR) into an active signaling state by uncoupling GCPR from the cytoskeleton. The receptor uncoupling results in respiratory burst activity when signals generated by reactivated formyl peptide receptors trigger the NADPH-oxidase to produce superoxide anions. RESULTS: Tumor necrosis factor alpha (TNF-alpha) primes neutrophils for subsequent activation by Cytochalasin B. Pretreatment with TNF-alpha induced mobilization of receptor-storing neutrophil organelles, suggesting that receptor up-regulation significantly contributes to the response, but the receptor mobilization was not sufficient for induction of the Cytochalasin B sensitive state. The TNF-alpha primed state resembled that of the desensitized non-signaling state of agonist-occupied neutrophil formyl peptide receptors. The fact that the TNF-alpha primed, Cytochalasin B-triggered activation process was pertussis toxin sensitive suggests that the activation process involves a GPCR. Based on desensitization experiments the unidentified receptor was found to be distinct from the C5a receptor as well as the formyl peptide receptor family members FPR and FPRL1. Based on the fact the occupied and desensitized receptors for interleukin-8 and platelet activating factor could not be reactivated by Cytochalasin B, also these could be excluded as receptor candidates involved in the TNF-alpha primed state. CONCLUSIONS: The TNF-alpha-induced priming signals could possibly trigger a release of an endogenous GPCR-agonist, amplifying the response to the receptor-uncoupling effect of Cytochalasin B. However, no such substance could be found, suggesting that TNF-alpha can transfer G-protein coupled receptors to a signaling state independently of agonist binding.
Cytochalasin B-induced membrane vesicles convey angiogenic activity of parental cells.[Pubmed:29050297]
Oncotarget. 2017 Jul 31;8(41):70496-70507.
Naturally occurring extracellular vesicles (EVs) play essential roles in intracellular communication and delivery of bioactive molecules. Therefore it has been suggested that EVs could be used for delivery of therapeutics. However, to date the therapeutic application of EVs has been limited by number of factors, including limited yield and full understanding of their biological activities. To address these issues, we analyzed the morphology, molecular composition, fusion capacity and biological activity of Cytochalasin B-induced membrane vesicles (CIMVs). The size of these vesicles was comparable to that of naturally occurring EVs. In addition, we have shown that CIMVs from human SH-SY5Y cells contain elevated levels of VEGF as compared to the parental cells, and stimulate angiogenesis in vitro and in vivo.
Changes in subcellular localization of visfatin in human colorectal HCT-116 carcinoma cell line after cytochalasin B treatment.[Pubmed:25308845]
Eur J Histochem. 2014 Sep 12;58(3):2408.
The aim of the study was to assess the expression and subcellular localization of visfatin in HCT-116 colorectal carcinoma cells after cytokinesis failure using Cytochalasin B (CytB) and the mechanism of apoptosis of cells after CytB. We observed translocation of visfatin's antigen in cytB treated colorectal carcinoma HCT-116 cells from cytosol to nucleus. Statistical and morphometric analysis revealed significantly higher area-related numerical density visfatin-bound nano-golds in the nuclei of cytB-treated HCT-116 cells compared to cytosol. Reverse relation to visfatin subcellular localization was observed in un-treated HCT-116 cells. The total amount of visfatin protein and visfatin mRNA level in HCT-116 cells was also decreased after CytB treatment. Additionally, CytB significantly decreased cell survival, increased levels of G2/M fractions, induced bi-nuclei formation as well as increased reactive oxygen species (ROS) level in HCT-116 cells. CytB treatment showed cytotoxic effect that stem from oxidative stress and is connected with the changes in the cytoplasmic/nuclear amount of visfatin in HCT-116 cells.
Compartmentalization of transport and phosphorylation of glucose in a hepatoma cell line.[Pubmed:15473866]
Biochem J. 2005 Mar 1;386(Pt 2):245-53.
The first steps of glucose metabolism are carried out by members of the families of GLUTs (glucose transporters) and HKs (hexokinases). Previous experiments using the inhibitor of glucose transport, CB (Cytochalasin B), revealed that compartmentalization of GLUTs and HKs is a major factor in the control of glucose uptake in L6 myotubes [Whitesell, Ardehali, Printz, Beechem, Knobel, Piston, Granner, Van Der Meer, Perriott and May (2003) Biochem. J. 370, 47-56]. In the present paper, we evaluate compartmentalization of GLUTs and HKs in a hepatoma cell line, H4IIE, which is characterized by excess GLUT activity, HKI in a particulate and a cytosolic fraction, and insignificant G6Pase (glucose-6-phosphatase) activity. The measured activity of glucose transport exceeded the rate of phosphorylation approx. 30-fold. Treatment with 25 microM CB (K(i) approximately 3 microM in H4IIE cells) paradoxically increased the excess of GLUTs over phosphorylation (GLUTs are inhibited 80%, while phosphorylation is inhibited 98%). The global relationships of the data could be reconciled most simply by a two-compartment model. In this model, phosphorylation of glucose is carried out by a subset of HK molecules supplied by a subset of GLUTs that are more sensitive to CB than the other GLUTs. The agent, DCC (dicyclohexylcarbodi-imide) caused HKI to translocate from the particulate compartment to the cytosolic compartment and potently inhibited glucose phosphorylation. The particulate compartment may represent the mitochondria, to which the more CB-sensitive GLUTs may control the transport of glucose.
Cytochalasin B may shorten actin filaments by a mechanism independent of barbed end capping.[Pubmed:8204105]
Biochem Pharmacol. 1994 May 18;47(10):1875-81.
It is generally accepted that Cytochalasin B (CB), as well as other cytochalasins, shorten actin filaments by blocking monomer addition at the fast-growing ("barbed") end of these polymers. Despite the predominance of this mechanism, recent evidence suggests that other interactions may also occur between CB and F-actin. To investigate this possibility further we have employed an actin derivative, prepared by substitution at Cys374 by a glutathionyl residue. We demonstrate here that CB did not significantly bind to glutathionyl F-actin under several ionic conditions. We further show that in the presence of CB the glutathionyl-F-actin exhibits a significantly higher ATPase activity than the non-modified F-actin. These data argue that the incorporation of glutathionyl groups prevents the high-affinity binding of CB to the barbed end of actin filaments, probably due to a decreased hydrophobicity of the CB binding site by the introduction of the hydrophilic glutathionyl residue. Despite the lack of substantial binding at equilibrium, we have found that the addition of CB to glutathionyl-F-actin results in extensive fragmentation of the filaments, as demonstrated by electron microscopy and by a significant reduction of the relative viscosity of actin solutions. These results are consistent with the idea that CB shortens glutathionyl-actin filaments by a mechanism distinct from barbed end capping. Glutathionyl F-actin offers an interesting model to study the complex mechanism of interaction of actin filaments with cytochalasins and with the physiologically important actin capping/severing proteins.
